Retired employee representatives return to "mother's home"
Release time:
2020-08-14
Retired Employees Return to "Mother's Family"
News "Peak has developed so fast in recent years, it is really not easy!" "I am so happy to see the enterprise getting better and better." At the spring tea party for retired employees on August 9 11, the representative of the retired employees of the peak was pleased to say after listening to the introduction of Jiang Xiaomeng, chairman of the group company, on the development of the peak in the past ten years. Company currently has more than 1400
19 retired employees attending the tea party are over 80 years old and "young" have retired for nearly 10 years. Yu Jianhong, general manager of the group company, said when presiding over the tea party that the peak was able to go through the course of nearly 60 years, relying on the peak spirit continuously summarized and condensed by the previous peak people. In recent years, the peak has been developing outside the province, but the peak spirit has always been unchanged. Wherever the enterprise does it, the peak spirit will be publicized. Because of this, we can face adversity indomitable, constantly overcome difficulties and steady development. At the tea party, Chairman Jiang Xiaomeng comprehensively introduced the current development of the company from several aspects, such as the development context of the company's various industries, improving internal management, doing a good job in accurate investment, introducing and training talents, and establishing a rigorous management system and incentive assessment system. Jiang Xiaomeng said that in the future, the company will adhere to the strategy of "cooperative innovation to strengthen the main business, standardize science and seek development", develop cement in areas with resources, markets, and relatively gentle competition, and in-depth cooperation with enterprises with potential and innovative capabilities to develop medicine. at the same time, vigorously develop health, trade and logistics, do a good job in internal management and external investment management, and ensure the competitive advantage of enterprises.
As the representatives attending the tea party have retired for many years, the company specially arranged for its subordinate enterprises to shoot video clips. Through the lens, the management teams of the enterprises expressed their gratitude to the predecessors for their hard work and extended their best wishes for the New Year.
After the tea party, Qin Xuping, chairman of the group's trade union, accompanied representatives of retired employees to visit Jinxi Pharmaceutical Factory. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31